Compounding ban ‘a significant public health concern’

Government urged to roll back its ban on compounding weight loss drugs  Banning the compounding of glucagon-like peptide-2 receptor agonists (GLP-1RAs) medications will limit patient access to the weight loss treatments, the Australia Society of Compounding Pharmacists (ASCP) warns.   Responding to the government’s planned prohibition on compounding of the medications, the group called on